ZIV-Aflibercept + Cemiplimab
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Uveal Melanoma
Conditions
Metastatic Uveal Melanoma
Trial Timeline
Nov 4, 2024 → Oct 31, 2030
NCT ID
NCT06121180About ZIV-Aflibercept + Cemiplimab
ZIV-Aflibercept + Cemiplimab is a phase 2 stage product being developed by Sanofi for Metastatic Uveal Melanoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06121180. Target conditions include Metastatic Uveal Melanoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Uveal Melanoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06121180 | Phase 2 | Recruiting |
Competing Products
20 competing products in Metastatic Uveal Melanoma